Antiallergic drugs, azelastine hydrochloride and epinastine hydrochloride, inhibit ongoing IgE secretion of rat IgE-producing hybridoma FE-3 cells

European Journal of Pharmacology

Volumn 547, Issue 1-3, 2006, Pages 174-183

  Hanashiro, Kazuhiko ^a   Sunagawa, Masanori ^a   Tokeshi, Yoshihiro ^a   Nakasone, Toshiyuki ^b   Ohta, Shigeto ^b   Nakamura, Mariko ^a   Kosugi, Tadayoshi ^a  

^a Rhukyu University School of Medicine   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Activation induced cytidine deaminase (AID); Antiallergic drug; I kappa B alpha (I B ); IgE; Nuclear factor kappa B (NF B)

Indexed keywords

ANTIALLERGIC AGENT; AZELASTINE; CYTIDINE DEAMINASE; EPINASTINE; I KAPPA B ALPHA; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HYBRIDOMA CELL CULTURE; IMMUNOGLOBULIN PRODUCTION; IMMUNOPRECIPITATION; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; WESTERN BLOTTING;

ANIMALS; ANTI-ALLERGIC AGENTS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CYTIDINE DEAMINASE; DIBENZAZEPINES; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION; HEAT-SHOCK PROTEINS; HYBRIDOMAS; I-KAPPA B PROTEINS; IMIDAZOLES; IMMUNOGLOBULIN E; MOLECULAR CHAPERONES; NEOPLASM PROTEINS; NF-KAPPA B; OLIGONUCLEOTIDES; PHOSPHORYLATION; PHTHALAZINES; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN KINASE C-EPSILON; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 33748580279     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.07.012     Document Type: Article

References (47)

1. Abe S., Ito Y., and Davies E. Cosedimentation of actin, tubulin and membranes in the cytoskeleton fractions from peas and mouse 3T3 cells. J. Exp. Bot. 43 (1992) 941-949
2. Ahluwalia J.P., Topp J.D., Weirather K., Zimmerman M., and Stamnes M. A role for calcium in stabilizing transport vesicle coats. J. Biol. Chem. 276 (2001) 34148-34155
3. Amon U., Gibbs B.F., Buss G., and Nitschke M. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm. Res. 49 (2000) 112-116
4. Arulampalam V., Eckhardt L., and Pettersson S. The enhancer shift: a model to explain the developmental control of IgH gene expression in B-lineage cells. Immunol. Today 18 (1997) 549-554
5. Calame K.L., Lin K.I., and Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu. Rev. Immunol. 21 (2003) 205-230
6. Dariavach P., Williams G.T., Campbell K., Pettersson S., and Neuberger M.S. The mouse IgH 3′-enhancer. Eur. J. Immunol. 21 (1991) 1499-1504
7. Dedeoglu F., Horwitz B., Chaudhuri J., Alt F.W., and Geha R.S. Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB. Int. Immunol. 16 (2004) 395-404
8. Durandy A. Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. Eur. J. Immunol. 33 (2003) 2069-2073
9. Fukuishi N., Kan T., Hirose K., Akagi R., and Akagi M. Inhibitory effect of epinastine on superoxide generation by rat neutrophils. Jpn. J. Pharmacol. 68 (1995) 449-452
10. Furue M., Osada A., Chang C.H., and Tamaki K. Immunosuppressive effects of azelastine hydrochloride on contact hypersensitivity and T-cell proliferative response: a comparative study with FK-506. J. Invest. Dermatol. 103 (1994) 49-53
11. Geha R.S., Jabara H.H., and Brodeur S.R. The regulation of immunoglobulin E class-switch recombination. Nat. Rev., Immunol. 3 (2003) 721-732
12. Hamasaki Y., Shafigeh M., Yamamoto S., Sato R., Zaitu M., Muro E., Kobayashi I., Ichimaru T., Tasaki H., and Miyazaki S. Inhibition of leukotriene synthesis by azelastine. Ann. Allergy, Asthma, & Immun. 76 (1996) 469-475
13. Hanashiro K., Tamaki N., Nakamura M., and Kosugi T. Proposal of the new concepts of antiallergic drugs from the results of animal experiments. Jpn. J. Inflammation 14 (1994) 499-507
14. Hanashiro K., Nakamura M., Tamaki N., and Kosugi T. Production of a monoclonal dinitrophenyl-specific rat IgE and establishment of an IgE capture ELISA for estimating the concentration of rat IgE antibodies to dinitrophenyl-Ascaris suum. Int. Arch. Allergy Immunol. 110 (1996) 371-379
15. Hanashiro K., Tokeshi Y., Nakasone T., Sunagawa M., Nakamura M., and Kosugi T. Azelastine and suplatast shorten the distribution half-life of IgE in rats. Mediat. Inflamm. 11 (2002) 61-64
16. Herrin, D.L., Schmidt, G.W., 1988. Rapid, reversible staining of northern blots prior to hybridization. Biotechniques. 6, 196-197, 199-200.
17. Hide I., Toriu N., Nuibe T., Inoue A., Hide M., Yamamoto S., and Nakata Y. Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation. J. Immunol. 159 (1997) 2932-2940
18. Honjo T., Muramatsu M., and Fagarasan S. AID: how does it aid antibody diversity?. Immunity 20 (2004) 659-668
19. Inagaki N., Nagao M., Nakamura N., Kawasaki H., Igeta K., Musoh K., and Nagai H. Evaluation of anti-scratch properties of oxatomide and epinastine in mice. Eur. J. Pharmacol. 400 (2000) 73-79
20. Iwakoshi N.N., Lee A.H., and Glimcher L.H. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol. Rev. 194 (2003) 29-38
21. Kamei C., Akagi M., Mio M., Kitazumi K., Izushi K., Masaki S., and Tasaka K. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol. Immunotoxicol. 14 (1992) 191-205
22. Kempuraj D., Huang M., Kandere-Grzybowska K., Basu S., Boucher W., Letourneau R., Athanassiou A., and Theoharides T.C. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int. Arch. Allergy Immunol. 132 (2003) 231-239
23. Kim E.C., Edmonston C.R., Wu X., Schaffer A., and Casali P. The HoxC4 homeodomain protein mediates activation of the immunoglobulin heavy chain 3′ hs1,2 enhancer in human B cells. Relevance to class switch DNA recombination. J. Biol. Chem. 279 (2004) 42258-42269
24. Kohyama T., Takizawa H., Akiyama N., Sato M., Kawasaki S., and Ito K. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem. Biophys. Res. Commun. 230 (1997) 125-128
25. 2+ current in guinea pig cardiac preparations. Eur. J. Pharmacol. 418 (2001) 7-14
26. Lin K.I., Tunyaplin C., and Calame K. Transcriptional regulatory cascades controlling plasma cell differentiation. Immunol. Rev. 194 (2003) 19-28
27. Logan M.R., Odemuyiwa S.O., and Moqbel R. Understanding exocytosis in immune and inflammatory cells: the molecular basis of mediator secretion. J. Allergy Clin. Immunol. 111 (2003) 923-932 (quiz 933)
28. Ma Y., and Hendershot L.M. Herp is dually regulated by both the endoplasmic reticulum stress-specific branch of the unfolded protein response and a branch that is shared with other cellular stress pathways. J. Biol. Chem. 279 (2004) 13792-13799
29. Matsukura M., Yajima A., Yamazaki F., Yudate T., Yamada H., and Tezuka T. Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis. Skin Pharmacol. Appl. Skin Physiol. 16 (2003) 405-410
30. Matsuo S., and Takayama S. Influence of the anti-allergic agent, azelastine, on tumor necrosis factor-alpha (TNF-alpha) secretion from cultured mouse mast cells. In Vivo 12 (1998) 481-484
31. Michaelson J.S., Singh M., Snapper C.M., Sha W.C., Baltimore D., and Birshtein B.K. Regulation of 3′ IgH enhancers by a common set of factors, including kappa B-binding proteins. J. Immunol. 156 (1996) 2828-2839
32. Nakasone T., Hanashiro K., Nakamura M., Sunakawa H., and Kosugi T. An improved method for the detection of IgE FE-3 by ELISA using monoclonal anti-IgE FE-3 antibody. Ryukyu Med. J. 20 (2001) 129-135
33. Nakata Y., and Hide I. Calcium signaling and protein kinase C for TNF-alpha secretion in a rat mast cell line. Life Sci. 62 (1998) 1653-1657
34. Ong J., Stevens S., Roeder R.G., and Eckhardt L.A. 3′ IgH enhancer elements shift synergistic interactions during B cell development. J. Immunol. 160 (1998) 4896-4903
35. Sepulveda M.A., Emelyanov A.V., and Birshtein B.K. NF-kappaB and Oct-2 synergize to activate the human 3′ Igh hs4 enhancer in B cells. J. Immunol. 172 (2004) 1054-1064
36. Shen X., Zhang K., and Kaufman R.J. The unfolded protein response-a stress signaling pathway of the endoplasmic reticulum. J. Chem. Neuroanat. 28 (2004) 79-92
37. Shimojo J. The effect of azelastine on bronchial mucosa in bronchial asthma-suppression of cytokine mRNA. Arerugi 47 (1998) 604-613
38. Shindo K., and Fukumura M. Azelastine hydrochloride inhibits platelet activating factor-like activity in human eosinophils. Prostaglandins Leukot. Essent. Fat. Acids 55 (1996) 217-221
39. Shindo K., Fukumura M., Hirai Y., and Koide K. Effect of azelastine hydrochloride on release and production of platelet activating factor in human neutrophils. Prostaglandins Leukot. Essent. Fat. Acids 56 (1997) 373-377
40. Shindo K., Machida M., Hirai Y., and Fukumura M. Inhibitory effect of azelastine hydrochloride on synthesis and release of platelet activating factor from human alveolar macrophages. Prostaglandins Leukot. Essent. Fat. Acids 57 (1997) 561-566
41. Silver R.B., and Pappas G.D. Secretion without membrane fusion: porocytosis. Anat. Rec. B. New. Anat. 282 (2005) 18-37
42. Sriburi R., Jackowski S., Mori K., and Brewer J.W. XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J. Cell Biol. 167 (2004) 35-41
43. Steen M.L., Hellman L., and Pettersson U. Rat immunoglobulin E heavy chain locus. J. Mol. Biol. 177 (1984) 19-32
44. 2+-dependent signal transduction pathways. J. Immunol. 155 (1995) 4685-4691
45. Tasaka K. Epinastine: an update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today 36 (2000) 735-757
46. Tokeshi Y., Shimada S., Hanashiro K., Sunagawa M., Nakamura M., and Kosugi T. The nucleotide sequence of dinitrophenyl-specific IgE and FcεRI α-subunit obtained from FE-3 hybridoma cells. Hybrid. Hybridomics 20 (2001) 361-368
47. Yoneda K., Yamamoto T., Ueta E., and Osaki T. Suppression by azelastine hydrochloride of NF-kappa B activation involved in generation of cytokines and nitric oxide. Jpn. J. Pharmacol. 73 (1997) 145-153